© Wolf G Kroner 2018 - Prof. Thomas D SzucsSteering Health Data for or by?
The User as Stakeholder, Expert, Citizen, Consumer, and Patient

January 2018. “Big data” has been a buzz word in healthcare industries for a number of years. Prof. Szucs, Chairman of Swiss Helsana AG has been dealing with it from many different angles: be it as physician in medical care, in pharma, academic teaching and research, in consulting, lobbying, or of course, as individual recipient of healthcare. He knows to winnow the real assets from advertisement blah-blah about big data, and he puts this knowledge to work. At issue is the management of fleeting roles of participants in healthcare.

In the interview with B2Bioworld Tomas Szucs shares his experience, addresses challenges which even a big, data-driven insurer is unable to tackle on its own, and suggests the way forward. Insurers like the rest of the healthcare industry have to cope with the upcoming profound change in the system, but they also must do their duties.

If you like to read this article, you can purchase it now

Please notice, If you order by email from an organisation - for-profit or nonprofit alike - you must buy an organisation sharing license and cannot buy an individual license. However the organisation sharing license entitles you to share the article with up to four other individuals - provided you adhere to the Terms and Conditions which you agree with when purchasing articles of B2Bioworld.

Read Now - Please select your license (Prices incl. 7% VAT)
11 pages free of advertisement

Article free of advertisement
- Includes Comments by Wolf G Kroner;
- Added information on the Swiss health insurance system and business performance; Schrems vs. Facebook Ireland; on insurance decision making for Huntington chorea; and debates about cases of discriminated persons assumed or genetically tested to be 100 at risk of disease.

Full Company License enquire here

Back to section

Related Editorial Articles

B2Bioworld offers you background information

Regulatory Challenges of Big Data Operations – Algorithms, Healthcare, or Autonomous Driving
Herbert Zech, Professor of Life Sciences and Intellectual Property Laws at Universität Basel on key juridical concepts of the current debate about big data and artificial intelligence applications beyond privacy laws

Roche prepares for user innovation
Ursula Redeker, CEO of Roche Germany about managing “big health data”, insourcing missing expertise, and linking up to the ecosystem

Metrics for Disease, Health, and Wellness
Personalized medicine? A systems look at human genetic diagnostics and the road ahead for next-generation sequencing by Leroy Hood, Institute for Systems Biology at Seattle

Doing our business a little bit differently than the others in industry
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk on stem cell approaches to diabetes

Transition of Cancer Research Translation
Christof von Kalle, Head of Germany’s National Center for Tumor Diseases on transitions in translational cancer research

Systems Biology Applied
Rudi Balling, Director of the Luxembourg Centre for Systems Biomedicine, on the need of systems theory thinking in using technologies and pitfalls of some concepts

Clarifying the concept of personalised medicine: Stem Cells - a discovery tool and a potential therapeutic modality.
Jonathan Knowles, Former Member of the Roche Executive Committee and Head of Group Research

Adhering to Values Pays Off
Novartis continues to expand the biotech therapeutics pipeline / Focus on emerging markets

Patient-centered Precision Care
Michael Christman, President of Coriell Institute about turning research on human genotyping into healthcare routine

Diagnostic Microfluidics: Sample In – Results Out?
Marc Feiglin, past Chief Technology Officer Life Sciences at Tecan on electrowetting technology, blood diagnostic devices, weaknesses of competitors like Illumina, and prospects of clinical microfluidics

Opening up Emerging Markets for Rapid Diagnostics and Point-of-Care Assays
David Dolinger shares experience and insight. Do’s and don’ts in developing viable tests for medical, agricultural, or food diagnostics, and bringing these to low resource countries.